Staff names and roles have not yet been verified from the company’s official website.
Workforce
Company-wide headcount
Not yet publicly verified
Indiana headcount
Not yet publicly verified
Company-wide, Indiana, local and parent figures are shown separately. Reporting dates may be older than the date checked. Unavailable figures remain unverified.
Aquestive Therapeutics said it will report third quarter 2026 financial results and recent business highlights after market close on November 3, 2026, and will host an investor conference call on November 4, 2026 at 8:00 a.m. ET. The company stated investors must register in advance to participate and that a live webcast and a replay (archived for 30 days) will be available on the Investors section of Aquestive’s website. Aquestive noted its New Jersey headquarters and U.S. manufacturing in Indiana.
Aquestive Therapeutics said the FDA has acknowledged its NDA resubmission for Anaphylm™ (dibutepinephrine) sublingual film as complete and classified the resubmission as a Class 2 response. The company reported the FDA assigned a PDUFA goal date of March 16, 2027. Aquestive stated it submitted the resubmission on September 16, 2026, and that its ex-U.S. plan remains on track with a planned Health Canada New Drug Submission in Q4 2026.
Aquestive announced that it entered an exclusive U.S. licensing and supply agreement with Eton Pharmaceuticals for LIBERVANT® (diazepam) buccal film. According to Aquestive, the product has Orphan Drug designation, issued patent protection extending into 2038, and tentative FDA approval in certain pediatric and adult age groups. Aquestive states Eton anticipates commercial availability in April 2027, subject to final FDA approval. Company-reported patient research showed 71% preference for buccal film over nasal spray, and the U.S. seizure rescue market was described as exceeding $450 million annually.
Aquestive Therapeutics announced that Rich Daly will join its Board of Directors effective October 14, 2026. The company said Mr. Daly brings more than 30 years of leadership in large and emerging biopharmaceutical companies with commercial and operating experience. Aquestive stated the Board will consist of eight directors after the appointment, seven of whom the Board has determined are independent under Nasdaq listing standards, and highlighted Daly's experience supporting commercial launches and building commercial organizations.
